Abstract
Through the studies of patients with hypophosphatemic rickets/osteomalacia, fibroblast growth factor 23(FGF23)has emerged as a humoral factor that reduces serum phosphate. Discovery of FGF23 as an essential regulator of phosphate homeostasis has markedly improved our understanding of phosphate homeostasis and hypophosphatemic or hyperphosphatemic disorders. A nationwide epidemiologic survey of FGF23-related hypophosphatemic diseases indicated that the patients showed FGF23 levels of above 30 pg/mL by intact assay in the presence of hypophosphatemia. The survey also showed that prevalence and biochemical data before and after treatment of the diseases. Novel therapeutic methods for these disorders may be developed by elucidation of the mechanism of action of FGF23.
MeSH terms
-
Animals
-
Biomarkers / blood
-
Extracellular Matrix Proteins / genetics
-
Fibroblast Growth Factor-23
-
Fibroblast Growth Factors / blood
-
Fibroblast Growth Factors / genetics
-
Fibroblast Growth Factors / physiology*
-
Homeostasis
-
Humans
-
Hypophosphatemia / diagnosis
-
Hypophosphatemia / epidemiology*
-
Hypophosphatemia / etiology
-
Hypophosphatemia / metabolism
-
Mice
-
Mutation
-
PHEX Phosphate Regulating Neutral Endopeptidase / genetics
-
Phosphates / metabolism
-
Phosphoproteins / genetics
-
Phosphoric Diester Hydrolases / genetics
-
Prevalence
-
Pyrophosphatases / genetics
-
Rickets, Hypophosphatemic / etiology
Substances
-
Biomarkers
-
DMP1 protein, human
-
Extracellular Matrix Proteins
-
FGF23 protein, human
-
Fgf23 protein, mouse
-
Phosphates
-
Phosphoproteins
-
Fibroblast Growth Factors
-
Fibroblast Growth Factor-23
-
Phosphoric Diester Hydrolases
-
ectonucleotide pyrophosphatase phosphodiesterase 1
-
PHEX Phosphate Regulating Neutral Endopeptidase
-
PHEX protein, human
-
Pyrophosphatases